Garry Neil, M.D.

Garry Neil, M.D.

DirectoratAvalo Therapeutics· In proxies 2022–2025

Pay in FY2025-47% from the year before · Avalo Therapeutics stock +144.4% the same year

Garry Neil, M.D. was paid $3.8M in FY2025 (Dec), down 47%. Avalo Therapeutics stock rose 144.4% that year.

Pay$100 in the stock at the end of FY21 → $0
Pay is from the Summary Compensation Table of each Avalo Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Celldex TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Avalo TherapeuticsPublic company · 4 yr
    • Chief Executive Officer, President and principal executive officer2022 – Present · 4 yrStock in role -100%
  3. Arena Pharmaceuticals, Inc.Public company · 9 yr
    • Director2017 – Present · 9 yrNo stock prices for these years
  4. Zura Bio LimitedPublic company
    • Director? – PresentNo stock prices for these years
  5. Zura Bio Ltd.Public company · Less than 1 yr
    • Director2023 – 2023 · Less than 1 yrNo stock prices for these years
  6. InnovationPublic company · 14 yr
    • Director2007 – 2021 · 14 yrNo stock prices for these years
  7. GTx, Inc.Public company · 3 yr
    • Director2016 – 2019 · 3 yrNo stock prices for these years
  8. TransCelerate Biopharma, Inc.Public company · 7 yr
    • Director2012 – 2019 · 7 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Avalo TherapeuticsDirector · 3 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?